

SAFETY DATA SHEET Alternet

Section 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier

Name of the substance: Alternet

Code:MAPP 17689

Formulation type: EC (emulsifiable concentrate)

Concentration: 250 g/L (25.7% w/w) Active substance: Difenoconazole

IUPAC-name: 3-chloro-4-[(2RS,4RS;2RS,4SR)-4-methyl-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-

2-yl]phenyl 4-chlorophenyl ether

Identification number: CAS 119446-68-3

RRN:No registration number is available for this substance, in accordance with the provisions of

Article 15 of Regulation (EC) No 1907/2006

1.2 Relevant identified uses of the substance or mixture and uses advised against

identified uses: fungicide for professional use

1.3 Details of the supplier of the safety data sheet



Belcrop NV Tiensestraat 300 3400 Landen Belgium

Tel.: +32 11 59 83 60 Fax: +32 11 59 83 61

Email: info@belcrop.be

1.4 Emergency telephone number

Please call the local emergency number

Emergency number in Belgium (24h/24, 7d/7): +32 11 69 79 80

Section 2: Hazards identification

2.1 Classification of the substance or mixture

Classification according to Regulation (EC) No 1272/2008

Asp. Tox. 1, Eye Dam. 1, Skin Irr. 2, STOT SE 3, Aquatic Chronic 1 H304, H315, H318, H336, H410

For full text of Hazard-statements see section 16.

2.2 Label elements

Label in accordance with Regulation (EC) No 1272/2008

Hazard pictogram

GHS05, GHS07, GHS08, GHS09:





Signal word Danger

hazard statement

H304: May be fatal if swallowed and enters airways.

H315: Causes skin irritation.

H318: Causes serious eye damage.

H336: May cause drowsiness or dizziness.

H410: Very toxic to aquatic life with long lasting effects.

EUH 401: To avoid risks to human health and the environment, comply with the instructions for use.

precautionary statement

P261: Avoid breathing spray.

P273: Avoid release to the environment.

P280: Wear protective gloves/protective clothing/eye protection/face protection.

P301 + P310: IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.

P302 + P352: IF ON SKIN: Wash with plenty of water/...

P305 + P351 + P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.

P391: Collect spillage.

P501: Dispose of contents/container in accordance with local/national regulation.

2.3 Other hazards

The active substance does not fulfill the criteria of a persistent, bioaccumulative and toxic (PBT) substance, nor of a very persistent and very bioaccumulative (vPvB) substance, as outlined in Annex XIII of Regulation (EC) No 1907/2006.

Section 3 : Composition/information on ingredients

3.2 Mixtures

Name	Identification number	RRN	% (% by weight)	Classification according to Regulation (EC) No 1272/2008
Difenoconazole	CAS 119446-68-3	not available	250 g/L (25.7% w/w)	Acute Tox. 4, Aquatic Acute 1, Aquatic Chronic 1 H302, H400, H410
Benzenesulfonic acid, C10-13-alkyl derivs., calcium salt	-	01- 2119560592- 37	<10%	Skin Irr. 2, Eye Dam. 1 H315, H318

SDS Alternet version: UK0,0



created: 16/12/2016 print date: 22/12/2016

Butan-1-ol	CAS 71-36-3	not available	<5%w/w	Flam. Liq. 3, Acute Tox. 4, Skin Irr. 2, Eye Dam. 1 H226, H302, H315, H318, H335, H336
N,N-dimethyloctanamide	CAS 1118-92-9	not available	<10%w/w	Acute Tox. 4, Skin Irr. 2, Eye Dam. 1 H302, H312, H315, H318
N,N-dimethyldecan-1-amide	CAS 14433-76- 2	not available	<10%w/w	Skin Irr. 2, Eye Irr. 2, Aquatic Chronic 2 H315, H319, H411
Hydrocarbons, C10, aromatics, <1% naphthalene	EC 918- 811-1	01- 2119463583- 34	<50%w/w	Asp. Tox. 1, Aquatic Chronic 2, STOT SE 3 H304, H411, H336, EUH 066

For full text of Hazard-statements see section 16.

Section 4: First aid measures

4.1 Description of first aid measures

If INHALED:

Fresh air, rest. Artificial respiration may be required. Call the emergency service, hospitalisation is recommended. Show the label or packaging.

In case of contact with SKIN:

Rinse the skin with plenty of water or take a shower for 15 minutes. Meanwhile, remove contaminated clothing and shoes. In case of symptoms, seek medical attention and show the label or packaging. In case of contact with EYES:

Rinse thoroughly with water for 10 minutes. Rinse AWAY from the non-affected eye. If wearing contact lenses: if easy to remove, first remove the lenses, then rinse. Consult a doctor and show the label or packaging.

If SWALLOWED:

Rinse the mouth. Do not induce vomiting. Call the emergency service, hospitalisation is recommended. Show the label or packaging.

4.2 Most important symptoms and effects, both acute and delayed

No data available in humans.

4.3 Indication of any immediate medical attention and special treatment needed

Notes to physician:

Prehospital: symptomatic treatment.

Contact the local poison center (see section 1.4) for further treatment in the hospital.

Section 5 : Fire fighting measures

5.1 Extinguishing media

Suitable extinguishing media: chemical powder, water spray, CO₂, polyvalent foam. Unsuitable extinguishing media: Water with full jet

5.2 Special hazards arising from the substance or mixture

The product contains flammable organic substances. In case of a fire, a thick black smoke containing hazardous products of combustion will be generated (see section 10). Exposure to decomposition products can be harmful to one's health.



5.3 Advice for fire-fighters

Self-contained breathing apparatus and full protective clothing (boots, overall, gloves, eye and face protection). Avoid discharge of extinguish water into sewer or watercourse.

Section 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

See section 8

6.2 Environmental precautions

Prevent the product from entering into soil, sewers, surface or ground water. If necessary, isolate the contaminated area. First remove spillage and accidental leaks (see section 6.3). Then rinse the contaminated area with water. Do not allow residues to enter into sewer and surface water. Dispose contaminated water according to local legislation. Inform the authorities if product pollutes the environment.

6.3 Methods and material for containment and cleaning up

6.3.1 Containment of a spill

If applicable, cover spillage with absorbing material (sand, clay, diatomite, universal binders, absorbing grain).

6.3.2 Clean-up of a spill

Spills shall be contained by means of absorbent material and a shovel. The collected products shall be disposed of in re-usable barrels or barrels for waste removal. As soon as the substance has been removed, thoroughly clean up the floor and any object that has been in contact with the substance in compliance with the environmental prescriptions.

6.3.3 Additional information

No additional information

6.4 Reference to other sections

See section 1 contact information See section 7 for handling and storage See section 8 for exposure controls/ personal protection See section 13 for disposal considerations

Section 7: Handling and storage

7.1 Precautions for safe handling

7.1.1 Protective measurements

Work under local exhaust/ventilation. Observe normal industrial and hygiene standards. Wear personnel protective clothing. Avoid contact with skin and eyes. Avoid forming of aerosol or dust. Wash hands after use. Do not discharge product into sewer. Keep away from source of ignition.

7.1.2 Advice on general occupational hygiene

When using, do not eat, drink or smoke. Clean used material. Wash hands after each use. Wash contaminated clothing after use. Remove contaminated clothing and protective equipment before entering eating areas

7.2 Conditions for safe storage, including any incompatibilities

Store in closed packaging in a dry, well ventilated area. Store in original packaging. Keep away from food, drink and animal feeding stuffs. Keep out of reach of children. See also section 10.



7.3 Specific end use(s)

See section 1.2.

Section 8 : Exposure controls/personal protection

8.1 Control parameters

8.1.1 Occupational exposure limit values

Butan-1-ol: 20 ppm

8.1.2 Information on currently recommended monitoring procedures

Not known

8.2 Exposure controls

8.2.1 Appropriate engineering controls

See section 7 and 8.1.1.

8.2.2 Individual protection measures, such as personal protective equipment

8.2.2.1 Eye / face protection

Wear safety goggles, with side-protection.

8.2.2.2 Skin protection

8.2.2.2.1 Hand protection

Wear chemical protective gloves (EN374).

8.2.2.2.2 other

Wear suitable work clothes. (Coverall with full body protection)

8.2.2.3 Respiratory protection

Use always in a well ventilated area.

Only if applicable:

Gas, vapours: gas filter: semi-facial mask with ABEK filter.

Dust, mist, fumes: dust mask: P2FFP2

8.2.3 Environmental exposure controls

See section 6: Accidental release measures

See section 7: storage and handling

See section 13: Disposal considerations

Section 9 : Physical and chemical properties

9.1 Information on basic physical and chemical properties

	Endpoint (unit)
a) Appearance	brown liquid
b) Odour	typical odour
c) Odour threshold	no data available
d) pH	6.5-7.5
e) Melting point/freezing point	no data available
f) Initial boiling point and boiling range	no data available
g) Flash point	61°C

SDS Alternet version: UK0,0



created: 16/12/2016 print date: 22/12/2016

h) Evaporation rate	no data available
i) Flammability (solid, gas)	no data available
j) Upper/lower flammability or explosive limits	not explosive
k) Vapour pressure	no data available
I) Vapour density	no data available
m) Relative density	0.989 g/ml (20°C)
n) Solubility(ies)	no data available
o) Partition coefficient: n-octanol/water	log Pow = 4.36 (active substance data, 25°C, pH 8)
p) Auto-ignition temperature	no data available
q) Decomposition temperature	no data available
r) Viscosity	no data available
s) Explosive properties	not explosive
t) Oxidising properties.	not oxidizing

9.2 Other information

No additional information

Section 10: Stability and reactivity

10.1 Reactivity

Stable under normal conditions of handling and storage.

10.2 Chemical stability

Stable under normal environmental temperatures (between 0°C and 40°C). See also section 7.2.

10.3 Possibility of hazardous reactions

No specific data known.

10.4 Conditions to avoid

No specific data known.

10.5 Incompatible materials

No specific data known.

10.6 Hazardous decomposition products

Combustion or thermal decomposition produces toxic and irritating vapours. See section 5.2

Section 11: Toxicological information

11.1 Information on toxicological effects

	endpoint	duration	species	tested on
a) acute toxicity	oral: LD50 = 1453 mg a.s./kg bw	single dose	rat	active substance (technical)
	dermal: LD50 > 2000 mg a.s./kg bw	24h	rabbit	active substance (technical)
	inhalation: LC50 > 3.3 mg a.s./L	4h exposure, nose only, highest technically achievable concentration	rat	active substance (technical)
b) skin corrosion/irritation	non-irritant	4h	rabbit	active substance (technical)

SDS Alternet version: UK0,0



created: 16/12/2016 print date: 22/12/2016

c) serious eye damage/irritation d) respiratory or skin sensitization e) germ cell mutagenicity Equivocal increases in chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity f) carcinogenicity g) reproductive toxicity g) reproductive toxicity f) STOT-single exposure i) aspiration in on-irritant 96h guinea pig active substance (technical) Chinese hamster ovary cells mouse Chinese hamster ovary cells mouse active substance (technical)			Ī	1	1
d) respiratory or skin sensitization e) germ cell mutagenicity Equivocal increases in chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity f) carcinogenicity g) reproductive toxicity g) reproductive toxicity h) STOT-single exposure i) sspiration e) germ cell (modified Buehler test) Equivocal increases in chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. Ever adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects no data available exposure i) strOT-repeated exposure i) aspiration no data available f) chromosomal active substance (technical) mouse active substance (technical) - rat - rat - rabbit - rat - rat	c) serious eye	non-irritant	96h	rabbit	active substance
skin sensitization e) germ cell Equivocal increases in chromosomal aberrations in CHO cells in vitro. Diffenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure i) aspiration reduced increases in chromosomal aberrations in CHO cells in vitro. Diffenoconazole is considered unlikely to pose a carcinogenic risk to humans. - Continuous exposure or 2 parental generations - days 7-19 of gestation - days 6-15 of gestation i) STOT-repeated exposure j) aspiration no data available	damage/irritation				(technical)
e) germ cell mutagenicity Equivocal increases in chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration reduced increases in chromosomal aberrations aberrations of the chromosomal active substance (technical) - rat -	d) respiratory or	non-sensitiser	6h	guinea pig	active substance
mutagenicity chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects no data available h) STOT-single exposure i) STOT-repeated exposure j) aspiration rowary cells ovary cells (technical) (technical) (technical) (technical) - rat - rat - rabbit - rat -	skin sensitization	(modified Buehler test)			(technical)
mutagenicity chromosomal aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects no data available h) STOT-single exposure i) STOT-repeated exposure j) aspiration rowary cells ovary cells (technical) mouse - continuous exposure for 2 parental generations - days 7-19 of gestation - continuous exposure for 2 parental generations - days 7-19 of gestation - rat - rat (technical) - rat - rabbit - rat - rabbit - rat - rabbit - rat - rat exposure for 2 parental generations - days 7-19 of gestation - days 6-15 of gestation - lovary cells (technical)	e) germ cell	Equivocal increases in	3h	Chinese hamster	active substance
aberrations in CHO cells in vitro. Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects mo data available h) STOT-single exposure i) STOT-repeated exposure j) aspiration no data available - In Modata available mouse mouse active substance (technical) - rat - rabbit - rat - rabbit - rat - rat - rabbit - rat - rat - rabbit - rat - rat - rat - rabbit - rat - rat - rat - rat - rabbit - rat - rat - rat - rabbit - rat - r	mutagenicity			ovary cells	(technical)
Difenoconazole is unlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects n) STOT-single exposure i) STOT-repeated exposure j) aspiration - Liver adenomas/carcinomas in mouse mouse mouse - rat - rat - rabbit - rat - rabbit - rat - rat - rabbit - rat active substance (technical) - rat - raboit - rat - raboit - rat - rat - raboit - rat - raboit - rat - raboit - rat - raboit - rat - rat - raboit - rat - rat - raboit - rat - rat - rat - rat - rat - raboit - rat - rat - rat - rat - raboit - rat - rat - rat - rat - rat - raboit - rat - rat		aberrations in CHO			,
tunlikely to be genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects n) STOT-single exposure i) STOT-repeated exposure j) aspiration radenomas/carcinomas in mouse mouse mouse active substance (technical) - rat - rabbit - rat active substance (technical) - rat - rabbit - rat active substance (technical) - rat oday 7-19 of gestation adverse effects no data available		cells in vitro.			
genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration mouse mouse mouse active substance (technical) - rat - rat - rabbit - rat odas 7-19 of gestation - days 7-19 of gestation - days 6-15 of gestation mouse active substance (technical) - rat - rabbit - rat odas 7-19 of gestation - days 6-15 of gestation no data available parental generations - days 6-15 of gestation - days 6-15 of gestation - odata available		Difenoconazole is			
genotoxic in vivo. f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration mouse mouse mouse active substance (technical) - rat - rat - rabbit - rat odas 7-19 of gestation - days 7-19 of gestation - days 6-15 of gestation mouse active substance (technical) - rat - rabbit - rat odas 7-19 of gestation - days 6-15 of gestation no data available parental generations - days 6-15 of gestation - days 6-15 of gestation - odata available		unlikely to be			
f) carcinogenicity Liver adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration - Itiver adenomas/carcinomas in mouse mouse mouse mouse active substance (technical) - rat - rabbit - rat active substance (technical) - rat - rabbit - rat odays 7-19 of gestation - days 6-15 of gestation mouse no data available					
adenomas/carcinomas in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects of sepsoure h) STOT-single exposure i) STOT-repeated exposure j) aspiration adenomas/carcinomas in mice, only at high doses where toxicity - Continuous exposure for 2 parental generations - days 7-19 of gestation - days 6-15 of gestation - days 6-15 of gestation - days 6-15 of gestation - days 6-15 of gestation - no data available - Tat - rat	f) carcinogenicity	Ť		mouse	active substance
in mice, only at high doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration in mice, only at high doses where toxicity was observed. - continuous - rat cotive substance (technical) - rat - rabbit - rat active substance (technical) - rat - rat out - rat - rat out - rat - rat out - rat - rab - rat - rat - rab - rat	1) caromogomony			1110000	
doses where toxicity was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration - Responsive toxicity - continuous - continuous - continuous - continuous - continuous - continuous - rat - rat - rat - rabbit - rat					(toormious)
was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration was observed. Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. - continuous exposure for 2 - rabbit - rat - rabbit - rat odays 7-19 of gestation - days 6-15 of gestation odata available roadverse effects no data available odata available - rat					
Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration - Difenoconazole is considered unlikely to pose a carcinogenic risk to humans. - continuous - rat - rat - rat (technical) - rat - rat - rat otive substance (technical)					
considered unlikely to pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects h) STOT-single exposure i) STOT-repeated exposure j) aspiration - Parental: reduced - continuous exposure for 2 parental generations - rat of technical) - rat packing exposure for 2 parental generations - rat of technical) - rat packing exposure for 2 parental generations - days 7-19 of gestation - days 7-19 of gestation - days 6-15 of gestation - days 6-15 of gestation - no data available - rat packing exposure for 2 parental generations - rat - rat packing exposure - rat pac					
pose a carcinogenic risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects i) STOT-single exposure j) aspiration pose a carcinogenic risk to humans. - continuous - rat - rat - rabbit - rat otive substance (technical) - rat - rat otive substance (technical)					
risk to humans. g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects i) STOT-repeated exposure j) aspiration risk to humans. - Parental: reduced body weight (gain) - continuous - rat - rabbit - rat - rat - rabbit - rat o data sys 7-19 of gestation - days 7-19 of gestation - days 6-15 of gestation o data available - rat o data sys 7-19 of gestation o data available - rat o data sys 7-19 of gestation o data available o data available o o data available o o data available o o data available					
g) reproductive toxicity - Parental: reduced body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects i) STOT-repeated exposure j) aspiration - Parental: reduced body weight (gain) - continuous exposure for 2 parental generations - days 7-19 of gestation - days 6-15 of gestation - rat - rat - rabbit - rat otive substance (technical) - rat - rat otive substance (technical) otive substance (technical) otive substance otive					
toxicity body weight (gain) - Offspring: reduced body weight trough lactation - Reproductive: no adverse effects i) STOT-repeated exposure j) aspiration body weight (gain) - Coffspring: reduced body weight trough - Coffspring: reduced parental generations - days 7-19 of gestation - days 6-15 of gestation o data available exposure i) STOT-repeated exposure body weight (gain) - rabbit - rat o days 7-19 of gestation o days 6-15 of gestation o days 6-15 of gestation o data available in o data available o data available o data available o data available	a) reproductive		- continuous	- rat	active substance
- Offspring: reduced body weight trough lactation - days 7-19 of gestation - days 6-15 of adverse effects no adverse effects no data available exposure i) STOT-repeated exposure j) aspiration no data available - rat	• .				
body weight trough lactation gestation - Reproductive: no adverse effects gestation h) STOT-single exposure i) STOT-repeated exposure j) aspiration look weight trough of gestation - days 7-19 of gestation - days 6-15 of gestation o data available rough of the productive: no adverse effects gestation o data available o data available in o data available	loziony				(teermiear)
lactation gestation - Reproductive: no adverse effects gestation h) STOT-single exposure i) STOT-repeated exposure j) aspiration no data available gestation - days 6-15 of gestation gestation - days 6-15 of gestation yestation - days 6-15 of gestation gestation - days 6-15 of gestation yestation - odata available				lat	
- Reproductive: no adverse effects gestation h) STOT-single exposure i) STOT-repeated exposure j) aspiration no data available - days 6-15 of gestation - days 6-15 of gestation					
adverse effects gestation h) STOT-single exposure i) STOT-repeated exposure j) aspiration no data available j) aspiration no data available		10.000			
h) STOT-single exposure no data available no data available exposure no data available exposure j) aspiration no data available					
exposure i) STOT-repeated no data available exposure j) aspiration no data available	h) STOT-single		gootation		
i) STOT-repeated exposure no data available no data available no data available	,	no data avallable			
exposure j) aspiration no data available	-	no data available			
j) aspiration no data available		no data avanabio			
" '	_	no data available			
		cata avanasio			

Section 12: Ecological information

12.1 Toxicity

	endpoint	duration	species	tested on
Acute toxicity fish	EC50 = 0.65 mg a.i./L	96h	Oncorhynchus mykiss	formulated product
Acute toxicity invertebrates	EC50 = 0.62 mg a.i./L	48h	Daphnia magna	formulated product
Algae	EyC50 = 1.01 mg a.i./L	72h	Scenedesmus subspicatus	formulated product

12.2 Persistence and degradability

DT50 (soil) = 130 days DT50 (water/sediment) = 315.5 days (active substance data)

12.3 Bioaccumulative potential

log Pow = 4.36 (active substance data, 25°C, pH 8)

bioconcentration factor (BCF) = 330 (some potential for bioaccumulation, but low risk for secondary poisoning) (active substance data)

12.4 Mobility in soil

Koc = 3759.4 mL/g (immobile to medium mobile) (active substance data)



12.5 Results of PBT and vPvB assessment

The active substance does not fulfill the criteria of a persistent, bioaccumulative and toxic (PBT) substance, nor of a very persistent and very bioaccumulative (vPvB) substance, as outlined in Annex XIII of Regulation (EC) No 1907/2006.

12.6 Other adverse effects

Section 13: Disposal considerations

13.1 Waste treatment methods

Product waste: prevent spreading. To be disposed of in compliance with local and national prescriptions.

Polluted packages: Do not re-use empty packages. If required, rinse 3 times. To be disposed of in compliance with local and national prescriptions.

Section 14: Transport information

		ADR classification	IMDG classification	IATA classification
14.1	UN number	3082	3082	3082
14.2	UN proper shipping name	environmentally hazardous substance, liquid, N.O.S. (difenoconazole)		
14.3	Transport hazard class(es)	9	9	9
14.4	Packing group	III	III	III
14.5	Environmental hazards	yes	yes	yes
14.6	Special precautions for user	Symbols: Tunnel code: E	Symbols:	Symbols:
14.7	Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code	Not applicable for road transport	Not applicable (not transported as bulk)	Not applicable for air transport

Section 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

SEVESO:

SEVESO category: E1



15.2 Chemical safety assessment

A chemical safety assessment has not been carried out for the substance or the mixture by the supplier.

Section 16: Other information

Relevant H-statements

H226: Flammable liquid and vapour.

H302: Harmful if swallowed.

H304: May be fatal if swallowed and enters airways.

H312: Harmful in contact with skin.

H315: Causes skin irritation.

H318: Causes serious eye damage.

H319: Causes serious eye irritation.

H335: May cause respiratory irritation.

H336: May cause drowsiness or dizziness.

H400: Very toxic to aquatic life.

H410: Very toxic to aquatic life with long lasting effects.

H411: Toxic to aquatic life with long lasting effects.

EUH 066: Repeated exposure may cause skin dryness or cracking.

EUH 401: To avoid risks to human health and the environment, comply with the instructions for use.

List of abbreviations and acronyms

RRN: REACH registration number

Changes to the previous version of safety data sheet.

First version

The information presented in this SDS is based on the current knowledge of the product and is derived from the existing literature. It is given in good faith and it only illustrates the aspect of security. This SDS is in addition with our information relating to the use of the formulation but in no case replaces it.

The users must be aware of the necessary precautions to take at the time of use or handling of this product. Consequently, the company can in, no case, be held responsible for damage which results, directly or indirectly, from the use of these data.

This Safety Data Sheet is in compliance with Regulation (EC) No 1907/2006, Regulation (EC) No 1272/2008, Regulation (EU) No 453/2010 and Regulation (EU) No 2015/830.